25 XP   0   0   10

PYC Therapeutics Ltd
Buy, Hold or Sell?

Let's analyse PYC Therapeutics Ltd together

PenkeI guess you are interested in PYC Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of PYC Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about PYC Therapeutics Ltd

I send you an email if I find something interesting about PYC Therapeutics Ltd.

Quick analysis of PYC Therapeutics Ltd (30 sec.)










What can you expect buying and holding a share of PYC Therapeutics Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.01
When do you have the money?
1 year
How often do you get paid?
30.0%

What is your share worth?

Current worth
A$0.01
Expected worth in 1 year
A$0.00
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
A$0.00
Return On Investment
-1.3%

For what price can you sell your share?

Current Price per Share
A$0.09
Expected price per share
A$0.077082352941177 - A$0.11501976284585
How sure are you?
50%

1. Valuation of PYC Therapeutics Ltd (5 min.)




Live pricePrice per Share (EOD)

A$0.09

Intrinsic Value Per Share

A$-0.09 - A$-0.04

Total Value Per Share

A$-0.08 - A$-0.03

2. Growth of PYC Therapeutics Ltd (5 min.)




Is PYC Therapeutics Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$18.4m$26m-$7.6m-41.3%

How much money is PYC Therapeutics Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$14.7m-$8.9m-$5.7m-39.2%
Net Profit Margin-144.2%-86.4%--

How much money comes from the company's main activities?

3. Financial Health of PYC Therapeutics Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#605 / 1019

Most Revenue
#302 / 1019

Most Profit
#624 / 1019

Most Efficient
#606 / 1019

What can you expect buying and holding a share of PYC Therapeutics Ltd? (5 min.)

Welcome investor! PYC Therapeutics Ltd's management wants to use your money to grow the business. In return you get a share of PYC Therapeutics Ltd.

What can you expect buying and holding a share of PYC Therapeutics Ltd?

First you should know what it really means to hold a share of PYC Therapeutics Ltd. And how you can make/lose money.

Speculation

The Price per Share of PYC Therapeutics Ltd is A$0.091. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of PYC Therapeutics Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in PYC Therapeutics Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.01. Based on the TTM, the Book Value Change Per Share is A$0.00 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of PYC Therapeutics Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps0.00-3.8%0.00-3.8%0.00-2.3%0.00-2.2%0.00-1.4%
Usd Book Value Change Per Share0.00-2.0%0.00-2.0%0.00-2.3%0.000.9%0.000.5%
Usd Dividend Per Share0.001.8%0.001.8%0.000.0%0.002.4%0.001.2%
Usd Total Gains Per Share0.00-0.2%0.00-0.2%0.00-2.3%0.003.3%0.001.6%
Usd Price Per Share0.04-0.04-0.04-0.06-0.04-
Price to Earnings Ratio-10.53--10.53--20.09--34.12--34.04-
Price-to-Total Gains Ratio-185.33--185.33--20.30--31.50--11.30-
Price to Book Ratio8.44-8.44-6.93-12.74-27.00-
Price-to-Total Gains Ratio-185.33--185.33--20.30--31.50--11.30-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0588952
Number of shares16979
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (16979 shares)-3.3650.37
Gains per Year (16979 shares)-13.45201.47
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1109-122-2314656191
2217-244-36292111392
3326-366-49437167593
4435-488-62583223794
5543-611-75729278995
6652-733-888753341196
7761-855-10110213901397
8869-977-11411674451598
9978-1099-12713125011799
101087-1221-14014585562000

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.019.01.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%6.04.00.060.0%11.09.00.055.0%
Dividend per Share1.00.00.0100.0%2.00.01.066.7%3.00.02.060.0%3.00.07.030.0%3.00.017.015.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%6.04.00.060.0%11.09.00.055.0%

Fundamentals of PYC Therapeutics Ltd

About PYC Therapeutics Ltd

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. The company's preclinical development programs include VP-001, a drug program for retinitis pigmentosa type 11; PYC-001, a drug program for the treatment of autosomal dominant optic atrophy; and PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

Fundamental data was last updated by Penke on 2024-04-03 05:06:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of PYC Therapeutics Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit PYC Therapeutics Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare PYC Therapeutics Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of -144.2% means that $-1.44 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of PYC Therapeutics Ltd:

  • The MRQ is -144.2%. The company is making a huge loss. -2
  • The TTM is -144.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-144.2%TTM-144.2%0.0%
TTM-144.2%YOY-86.4%-57.8%
TTM-144.2%5Y-326,600.1%+326,455.9%
5Y-326,600.1%10Y-201,903.9%-124,696.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-144.2%-196.9%+52.7%
TTM-144.2%-211.2%+67.0%
YOY-86.4%-279.3%+192.9%
5Y-326,600.1%-436.8%-326,163.3%
10Y-201,903.9%-599.3%-201,304.6%
1.1.2. Return on Assets

Shows how efficient PYC Therapeutics Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare PYC Therapeutics Ltd to the Biotechnology industry mean.
  • -61.3% Return on Assets means that PYC Therapeutics Ltd generated $-0.61 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of PYC Therapeutics Ltd:

  • The MRQ is -61.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -61.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-61.3%TTM-61.3%0.0%
TTM-61.3%YOY-30.6%-30.7%
TTM-61.3%5Y-41.0%-20.3%
5Y-41.0%10Y-73.6%+32.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-61.3%-13.6%-47.7%
TTM-61.3%-12.9%-48.4%
YOY-30.6%-11.9%-18.7%
5Y-41.0%-14.2%-26.8%
10Y-73.6%-16.2%-57.4%
1.1.3. Return on Equity

Shows how efficient PYC Therapeutics Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare PYC Therapeutics Ltd to the Biotechnology industry mean.
  • -82.1% Return on Equity means PYC Therapeutics Ltd generated $-0.82 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of PYC Therapeutics Ltd:

  • The MRQ is -82.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -82.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-82.1%TTM-82.1%0.0%
TTM-82.1%YOY-35.2%-46.9%
TTM-82.1%5Y-47.9%-34.2%
5Y-47.9%10Y-118.0%+70.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-82.1%-17.0%-65.1%
TTM-82.1%-16.1%-66.0%
YOY-35.2%-15.4%-19.8%
5Y-47.9%-20.0%-27.9%
10Y-118.0%-21.1%-96.9%

1.2. Operating Efficiency of PYC Therapeutics Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient PYC Therapeutics Ltd is operating .

  • Measures how much profit PYC Therapeutics Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare PYC Therapeutics Ltd to the Biotechnology industry mean.
  • An Operating Margin of -247.8% means the company generated $-2.48  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of PYC Therapeutics Ltd:

  • The MRQ is -247.8%. The company is operating very inefficient. -2
  • The TTM is -247.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-247.8%TTM-247.8%0.0%
TTM-247.8%YOY-188.3%-59.5%
TTM-247.8%5Y-568,478.3%+568,230.5%
5Y-568,478.3%10Y-344,267.3%-224,211.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-247.8%-282.4%+34.6%
TTM-247.8%-225.8%-22.0%
YOY-188.3%-288.4%+100.1%
5Y-568,478.3%-475.2%-568,003.1%
10Y-344,267.3%-624.7%-343,642.6%
1.2.2. Operating Ratio

Measures how efficient PYC Therapeutics Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.48 means that the operating costs are $2.48 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of PYC Therapeutics Ltd:

  • The MRQ is 2.478. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.478. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.478TTM2.4780.000
TTM2.478YOY1.883+0.595
TTM2.4785Y7,154.719-7,152.241
5Y7,154.71910Y4,242.520+2,912.199
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4782.994-0.516
TTM2.4783.247-0.769
YOY1.8833.766-1.883
5Y7,154.7195.675+7,149.044
10Y4,242.5207.857+4,234.663

1.3. Liquidity of PYC Therapeutics Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if PYC Therapeutics Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.79 means the company has $3.79 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of PYC Therapeutics Ltd:

  • The MRQ is 3.792. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.792. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.792TTM3.7920.000
TTM3.792YOY8.945-5.153
TTM3.7925Y16.028-12.236
5Y16.02810Y10.102+5.926
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7923.930-0.138
TTM3.7924.251-0.459
YOY8.9455.436+3.509
5Y16.0286.045+9.983
10Y10.1026.383+3.719
1.3.2. Quick Ratio

Measures if PYC Therapeutics Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare PYC Therapeutics Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 3.79 means the company can pay off $3.79 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of PYC Therapeutics Ltd:

  • The MRQ is 3.786. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.786. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.786TTM3.7860.000
TTM3.786YOY8.929-5.143
TTM3.7865Y32.202-28.416
5Y32.20210Y18.186+14.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7863.629+0.157
TTM3.7864.065-0.279
YOY8.9295.390+3.539
5Y32.2025.993+26.209
10Y18.1866.277+11.909

1.4. Solvency of PYC Therapeutics Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of PYC Therapeutics Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare PYC Therapeutics Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23 means that PYC Therapeutics Ltd assets are financed with 23.5% credit (debt) and the remaining percentage (100% - 23.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of PYC Therapeutics Ltd:

  • The MRQ is 0.235. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.235. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.235TTM0.2350.000
TTM0.235YOY0.114+0.121
TTM0.2355Y0.104+0.131
5Y0.10410Y0.202-0.098
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2350.332-0.097
TTM0.2350.333-0.098
YOY0.1140.268-0.154
5Y0.1040.366-0.262
10Y0.2020.390-0.188
1.4.2. Debt to Equity Ratio

Measures if PYC Therapeutics Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare PYC Therapeutics Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 31.4% means that company has $0.31 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of PYC Therapeutics Ltd:

  • The MRQ is 0.314. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.314. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.314TTM0.3140.000
TTM0.314YOY0.131+0.184
TTM0.3145Y0.126+0.188
5Y0.12610Y0.320-0.193
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3140.380-0.066
TTM0.3140.389-0.075
YOY0.1310.334-0.203
5Y0.1260.432-0.306
10Y0.3200.465-0.145

2. Market Valuation of PYC Therapeutics Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings PYC Therapeutics Ltd generates.

  • Above 15 is considered overpriced but always compare PYC Therapeutics Ltd to the Biotechnology industry mean.
  • A PE ratio of -10.53 means the investor is paying $-10.53 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of PYC Therapeutics Ltd:

  • The EOD is -16.903. Based on the earnings, the company is expensive. -2
  • The MRQ is -10.532. Based on the earnings, the company is expensive. -2
  • The TTM is -10.532. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-16.903MRQ-10.532-6.371
MRQ-10.532TTM-10.5320.000
TTM-10.532YOY-20.091+9.559
TTM-10.5325Y-34.120+23.588
5Y-34.12010Y-34.041-0.079
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-16.903-2.426-14.477
MRQ-10.532-2.552-7.980
TTM-10.532-2.656-7.876
YOY-20.091-4.143-15.948
5Y-34.120-6.252-27.868
10Y-34.041-6.108-27.933
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of PYC Therapeutics Ltd:

  • The EOD is -15.462. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -9.634. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.634. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-15.462MRQ-9.634-5.828
MRQ-9.634TTM-9.6340.000
TTM-9.634YOY-12.564+2.930
TTM-9.6345Y-36.442+26.808
5Y-36.44210Y-36.4420.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-15.462-3.199-12.263
MRQ-9.634-3.259-6.375
TTM-9.634-3.552-6.082
YOY-12.564-5.617-6.947
5Y-36.442-8.326-28.116
10Y-36.442-8.689-27.753
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of PYC Therapeutics Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 8.44 means the investor is paying $8.44 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of PYC Therapeutics Ltd:

  • The EOD is 13.543. Based on the equity, the company is expensive. -2
  • The MRQ is 8.438. Based on the equity, the company is overpriced. -1
  • The TTM is 8.438. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD13.543MRQ8.438+5.105
MRQ8.438TTM8.4380.000
TTM8.438YOY6.928+1.510
TTM8.4385Y12.736-4.298
5Y12.73610Y26.998-14.262
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD13.5431.947+11.596
MRQ8.4382.116+6.322
TTM8.4382.095+6.343
YOY6.9282.836+4.092
5Y12.7363.443+9.293
10Y26.9983.791+23.207
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of PYC Therapeutics Ltd.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of PYC Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.003-0.0030%-0.003+17%0.001-319%0.001-532%
Book Value Per Share--0.0070.0070%0.009-29%0.008-11%0.004+58%
Current Ratio--3.7923.7920%8.945-58%16.028-76%10.102-62%
Debt To Asset Ratio--0.2350.2350%0.114+107%0.104+126%0.202+16%
Debt To Equity Ratio--0.3140.3140%0.131+140%0.126+149%0.320-2%
Dividend Per Share--0.0020.0020%-+100%0.003-25%0.002+49%
Eps---0.005-0.0050%-0.003-39%-0.003-43%-0.002-63%
Free Cash Flow Per Share---0.006-0.0060%-0.005-11%-0.003-43%-0.002-64%
Free Cash Flow To Equity Per Share---0.003-0.0030%-0.005+66%0.001-632%0.001-691%
Gross Profit Margin--1.0421.0420%1.069-3%1.0450%1.023+2%
Intrinsic Value_10Y_max---0.042--------
Intrinsic Value_10Y_min---0.090--------
Intrinsic Value_1Y_max---0.003--------
Intrinsic Value_1Y_min---0.006--------
Intrinsic Value_3Y_max---0.009--------
Intrinsic Value_3Y_min---0.020--------
Intrinsic Value_5Y_max---0.017--------
Intrinsic Value_5Y_min---0.038--------
Market Cap385191159.808+38%240003722.650240003722.6500%278522838.630-14%359793940.480-33%229336890.532+5%
Net Profit Margin---1.442-1.4420%-0.864-40%-3266.001+226427%-2019.039+139939%
Operating Margin---2.478-2.4780%-1.883-24%-5684.783+229338%-3442.673+138846%
Operating Ratio--2.4782.4780%1.883+32%7154.719-100%4242.520-100%
Pb Ratio13.543+38%8.4388.4380%6.928+22%12.736-34%26.998-69%
Pe Ratio-16.903-60%-10.532-10.5320%-20.091+91%-34.120+224%-34.041+223%
Price Per Share0.091+38%0.0570.0570%0.066-14%0.085-33%0.054+5%
Price To Free Cash Flow Ratio-15.462-60%-9.634-9.6340%-12.564+30%-36.442+278%-36.442+278%
Price To Total Gains Ratio-297.449-60%-185.334-185.3340%-20.298-89%-31.502-83%-11.299-94%
Quick Ratio--3.7863.7860%8.929-58%32.202-88%18.186-79%
Return On Assets---0.613-0.6130%-0.306-50%-0.410-33%-0.736+20%
Return On Equity---0.821-0.8210%-0.352-57%-0.479-42%-1.180+44%
Total Gains Per Share--0.0000.0000%-0.003+960%0.005-107%0.002-113%
Usd Book Value--18408050.07318408050.0730%26018926.618-29%20589251.409-11%11654862.966+58%
Usd Book Value Change Per Share---0.002-0.0020%-0.002+17%0.001-319%0.000-532%
Usd Book Value Per Share--0.0040.0040%0.006-29%0.005-11%0.003+58%
Usd Dividend Per Share--0.0020.0020%-+100%0.002-25%0.001+49%
Usd Eps---0.003-0.0030%-0.002-39%-0.002-43%-0.001-63%
Usd Free Cash Flow---16123565.454-16123565.4540%-14347901.062-11%-9176318.469-43%-5749291.500-64%
Usd Free Cash Flow Per Share---0.004-0.0040%-0.003-11%-0.002-43%-0.001-64%
Usd Free Cash Flow To Equity Per Share---0.002-0.0020%-0.003+66%0.000-632%0.000-691%
Usd Market Cap249295718.628+38%155330409.299155330409.2990%180259981.162-14%232858638.279-33%148426835.552+5%
Usd Price Per Share0.059+38%0.0370.0370%0.043-14%0.055-33%0.035+5%
Usd Profit---14749031.092-14749031.0920%-8972236.505-39%-8455242.531-43%-5496953.915-63%
Usd Revenue--10229808.88310229808.8830%10382913.751-1%4830623.265+112%2691364.243+280%
Usd Total Gains Per Share--0.0000.0000%-0.002+960%0.003-107%0.001-113%
 EOD+5 -3MRQTTM+0 -0YOY+9 -275Y+6 -3010Y+17 -19

4.2. Fundamental Score

Let's check the fundamental score of PYC Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-16.903
Price to Book Ratio (EOD)Between0-113.543
Net Profit Margin (MRQ)Greater than0-1.442
Operating Margin (MRQ)Greater than0-2.478
Quick Ratio (MRQ)Greater than13.786
Current Ratio (MRQ)Greater than13.792
Debt to Asset Ratio (MRQ)Less than10.235
Debt to Equity Ratio (MRQ)Less than10.314
Return on Equity (MRQ)Greater than0.15-0.821
Return on Assets (MRQ)Greater than0.05-0.613
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of PYC Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.400
Ma 20Greater thanMa 500.088
Ma 50Greater thanMa 1000.084
Ma 100Greater thanMa 2000.088
OpenGreater thanClose0.097
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets37,166
Total Liabilities8,723
Total Stockholder Equity27,750
 As reported
Total Liabilities 8,723
Total Stockholder Equity+ 27,750
Total Assets = 37,166

Assets

Total Assets37,166
Total Current Assets31,873
Long-term Assets5,293
Total Current Assets
Cash And Cash Equivalents 15,572
Net Receivables 16,252
Other Current Assets 50
Total Current Assets  (as reported)31,873
Total Current Assets  (calculated)31,873
+/-0
Long-term Assets
Property Plant Equipment 1,043
Intangible Assets 4,250
Other Assets 0
Long-term Assets  (as reported)5,293
Long-term Assets  (calculated)5,293
+/- 0

Liabilities & Shareholders' Equity

Total Current Liabilities8,406
Long-term Liabilities318
Total Stockholder Equity27,750
Total Current Liabilities
Short-term Debt 178
Accounts payable 4,919
Other Current Liabilities 3,309
Total Current Liabilities  (as reported)8,406
Total Current Liabilities  (calculated)8,406
+/-0
Long-term Liabilities
Long term Debt Total 138
Other Liabilities 180
Long-term Liabilities  (as reported)318
Long-term Liabilities  (calculated)318
+/- 0
Total Stockholder Equity
Common Stock140,087
Retained Earnings -118,169
Accumulated Other Comprehensive Income 5,832
Total Stockholder Equity (as reported)27,750
Total Stockholder Equity (calculated)27,750
+/-0
Other
Capital Stock140,087
Cash And Equivalents15,572
Cash and Short Term Investments 15,572
Common Stock Shares Outstanding 3,210,594
Current Deferred Revenue-178
Liabilities and Stockholders Equity 37,166
Net Debt -15,256
Net Invested Capital 27,750
Net Tangible Assets 23,500
Net Working Capital 23,468
Property Plant and Equipment Gross 4,188
Short Long Term Debt Total 315



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-30
> Total Assets 
1,174
6,084
2,832
3,534
3,519
3,487
1,570
5,661
3,495
2,262
4,524
1,786
7,266
10,348
3,419
6,701
31,546
57,941
45,352
37,166
37,16645,35257,94131,5466,7013,41910,3487,2661,7864,5242,2623,4955,6611,5703,4873,5193,5342,8326,0841,174
   > Total Current Assets 
0
5,578
2,758
3,419
3,323
3,414
1,405
5,375
3,016
1,926
4,194
1,623
7,199
10,132
3,276
6,218
25,561
51,781
39,249
31,873
31,87339,24951,78125,5616,2183,27610,1327,1991,6234,1941,9263,0165,3751,4053,4143,3233,4192,7585,5780
       Cash And Cash Equivalents 
791
5,505
2,639
3,369
3,232
3,073
1,281
5,199
2,779
1,807
4,022
1,476
7,074
9,940
3,147
6,181
7,242
18,435
29,110
15,572
15,57229,11018,4357,2426,1813,1479,9407,0741,4764,0221,8072,7795,1991,2813,0733,2323,3692,6395,505791
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,186
18,186
33,067
0
0
0033,06718,18618,186000000000000000
       Net Receivables 
38
50
11
30
60
342
124
113
237
119
172
119
126
192
128
11
83
186
10,071
16,252
16,25210,07118683111281921261191721192371131243426030115038
       Other Current Assets 
0
22
108
21
31
0
0
62
0
0
0
28
0
0
0
26
50
93
68
50
50689350260002800062003121108220
   > Long-term Assets 
0
507
74
115
196
73
165
287
479
337
330
163
67
216
143
483
5,985
6,160
6,103
5,293
5,2936,1036,1605,9854831432166716333033747928716573196115745070
       Property Plant Equipment 
4
40
74
115
196
73
165
287
479
337
330
163
67
216
143
483
1,135
1,486
1,629
1,043
1,0431,6291,4861,135483143216671633303374792871657319611574404
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
300
0
0
0
0003000000000000000000
       Intangible Assets 
340
466
0
0
0
0
0
0
0
0
0
0
0
0
0
4,850
4,850
4,650
4,450
4,250
4,2504,4504,6504,8504,8500000000000000466340
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24
24
0
0242400000000000000000
> Total Liabilities 
628
304
718
1,337
824
1,576
2,007
1,308
801
1,068
805
824
1,436
1,489
1,772
402
1,351
4,017
5,149
8,723
8,7235,1494,0171,3514021,7721,4891,4368248051,0688011,3082,0071,5768241,337718304628
   > Total Current Liabilities 
628
304
718
1,326
814
535
1,982
1,259
777
1,049
800
824
1,436
1,489
1,772
402
706
3,297
4,388
8,406
8,4064,3883,2977064021,7721,4891,4368248001,0497771,2591,9825358141,326718304628
       Short-term Debt 
0
0
13
10
7
0
1,238
0
0
0
0
0
0
0
0
153
153
188
260
178
178260188153153000000001,23807101300
       Accounts payable 
72
17
221
579
260
330
561
543
367
718
411
444
1,057
1,446
1,684
194
97
2,346
2,574
4,919
4,9192,5742,346971941,6841,4461,0574444117183675435613302605792211772
       Other Current Liabilities 
3
225
339
498
546
205
183
716
410
331
389
379
379
43
88
208
455
763
1,554
3,309
3,3091,55476345520888433793793893314107161832055464983392253
   > Long-term Liabilities 
0
0
0
11
10
1,041
25
50
25
18
6
0
0
0
0
645
645
720
762
318
31876272064564500006182550251,0411011000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
645
543
684
138
1386845436450000000000000000
       Other Liabilities 
0
0
0
11
10
13
25
50
25
18
6
0
0
0
0
0
0
177
78
180
18078177000000618255025131011000
> Total Stockholder Equity
546
5,781
2,114
2,197
2,695
1,911
-437
4,353
2,694
1,195
3,719
962
5,830
8,859
1,647
6,299
28,453
53,044
39,352
27,750
27,75039,35253,04428,4536,2991,6478,8595,8309623,7191,1952,6944,353-4371,9112,6952,1972,1145,781546
   Common Stock
899
7,721
7,820
11,710
16,676
20,093
21,973
30,367
32,456
34,056
39,666
39,666
48,456
53,209
53,334
61,951
87,207
125,991
125,991
140,087
140,087125,991125,99187,20761,95153,33453,20948,45639,66639,66634,05632,45630,36721,97320,09316,67611,7107,8207,721899
   Retained Earnings Total Equity00000000000000000000
   Accumulated Other Comprehensive Income 
0
-7
283
-49
-98
671
1,015
1,016
1,174
1,514
545
780
837
1,064
1,161
1,276
4,996
8,570
8,741
5,832
5,8328,7418,5704,9961,2761,1611,0648377805451,5141,1741,0161,015671-98-49283-70
   Capital Surplus 00000000000000000000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
545
780
837
1,064
1,161
1,276
-23,457
-44,474
-30,611
-21,918
-21,918-30,611-44,474-23,4571,2761,1611,0648377805450000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.